Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125971042 | 12597104 | 2 | F | 20160625 | 20160720 | 20160727 | 20160803 | EXP | IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-120783 | RANBAXY | 62.15 | YR | F | Y | 0.00000 | 20160803 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125971042 | 12597104 | 1 | PS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 15 ML TOTAL | Y | U | 77032 | 15 | ML | ||||||
| 125971042 | 12597104 | 2 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 35 MG TOTAL | U | U | 0 | 35 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125971042 | 12597104 | 1 | Intentional self-injury |
| 125971042 | 12597104 | 2 | Intentional self-injury |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125971042 | 12597104 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125971042 | 12597104 | Drug abuse | |
| 125971042 | 12597104 | Hypokinesia | |
| 125971042 | 12597104 | Intentional self-injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125971042 | 12597104 | 1 | 20160625 | 20160625 | 0 | |
| 125971042 | 12597104 | 2 | 20160625 | 20160625 | 0 |